Calls for papers
-
Adherium has announced the appointment of Jane Lapon as Head of Global Market Access & Reimbursement, where she will be responsible for ensuring reimbursement for the Hailie inhaler monitoring platform. Lapon was most recently VP… Read more . . .
-
Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101… Read more . . .
-
AI Therapeutics (formerly LAM Therapeutics) said that it is seeking a partner to advance its LAM-001 inhaled rapamycin into Phase 3 trials for the treatment of lymphangioleiomyomatosis (LAM disease) and into Phase 2 for the… Read more . . .
-
According to MannKind Corporation, Brazil’s Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health… Read more . . .
-
UK-based device company Merxin has officially launched its new MRX006 multidose DPI, which has dual cavities and is designed specifically for triple therapies such as generic versions of Trelegy Ellipta. The company introduced the new… Read more . . .
-
Canadian CRO Impopharma, which specializes in OINDP analysis and development, has been acquired by Rubicon Research, Rubicon said. Impopharma’s Concord, ON facility will become Rubicon’s Nasal and Pulmonary Center of Excellence. Impopharma’s services included testing… Read more . . .
-
Seelos Therapeutics said that it has scheduled a Type C meeting with the FDA for March 2020 regarding a Phase 3 trial of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation… Read more . . .
-
Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix’s iSPERSE particle engineering technology for development… Read more . . .
-
ATAI Life Sciences has announced a deal with US-based Neuronasal Inc. for development of intranasal N-acetylcysteine (NAC) for the treatment of mild traumatic brain injury (mTBI, or concussion). ATAI said that it expects initiation of… Read more . . .
-
According to Pulmatrix, the Lung Cancer Initiative at Johnson & Johnson will pay $7.2 million up front plus a $2 million milestone payment for an option “to access a portfolio of narrow spectrum kinase inhibitors intended for development… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland